NCI Definition: An atypical lipomatous tumor/well differentiated liposarcoma that shows progression to a usually non-lipomatous, high grade sarcoma. The non-lipomatous sarcoma component may be present in the primary lesion or at the site of recurrence. 
Dedifferentiated liposarcomas most frequently harbor alterations in MDM2, CDK4, GLI1, TNFAIP3, and TERT .
MDM2 Amplification, CDK4 Amplification, GLI1 Amplification, TNFAIP3 Amplification, and TERT Amplification are the most common alterations in dedifferentiated liposarcoma .
There are 8 clinical trials for dedifferentiated liposarcoma, of which 8 are open and 0 are completed or closed. Of the trials that contain dedifferentiated liposarcoma as an inclusion criterion, 1 is phase 1 (1 open), 6 are phase 2 (6 open), and 1 is phase 2/phase 3 (1 open).
Nivolumab, selinexor, and apx005m are the most common interventions in dedifferentiated liposarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.